Table 1.
Participants' demographic and clinical characteristics in various COVID-19 vaccine regimens.
| 2 PastoCovac + PastoCovac Plus | 2 Sinopharm + PastoCovac Plus | 2 Sinopharm + PastoCovac | 2 AstraZeneca + PastoCovac Plus | 2 COVAXIN + PastoCovac Plus | 3 Sinopharm | 3 AstraZeneca | P Value | |
|---|---|---|---|---|---|---|---|---|
| Respondents | N = 84 | N = 49 | N = 49 | N = 45 | N = 32 | N = 37 | N = 12 | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||
| Age median (IQR) | 40 (29, 48) | 44 (37, 50) | 38 (26, 47) | 39 (31, 48) | 38 (33, 44) | 35 (27, 48) | 40 (30, 51) | 0.1347 |
|
| ||||||||
| Age group (year) | ||||||||
| <20 | 0 (0) | 0 (0) | 6 (12.2) | 0 (0) | 0 (0) | 2 (5.4) | 0 | |
| 20–30 | 22 (26.8) | 6 (12.2) | 10 (20.4) | 9 (20) | 5 (15.6) | 9 (24.3) | 2 (16.6) | |
| 30–40 | 24 (29.3) | 10 (20.4) | 11 (22.4) | 14 (31.1) | 14 (43.7) | 12 (37.5) | 4 (33.3) | |
| 40–50 | 20 (24.4) | 19 (38.7) | 12 (24.4) | 13 28.8) | 10 (31.2) | 8 (21.6) | 3 (25) | |
| >50 | 16 (19.5) | 14 (28.5) | 10 (20.4) | 9 (20) | 3 (9.3) | 6 (16.2) | 3 (25) | |
| BMI median (IQR) | 25.7 (23.4, 29.4) | 26.7 (23.9, 30.4) | 24.2 (23.1, 28.3) | 25.6 (23.9, 27.0) | 22.9 (21.2, 25.0) | 24.2 (22.8, 29.4) | 24.2 (21.7, 25.3) | 0.0025∗ |
|
| ||||||||
| BMI categories (kg/m2) | ||||||||
| 18–22 | 14 (17.7) | 5 (10.2) | 4 (33.3) | 9 (20) | 7 (21.8) | 6 (16.2) | 4 (33.3) | |
| 22–25 | 25 (30.5) | 11 (22.4) | 23 (46.9) | 9 (20) | 17 (53.1) | 14 (37.8) | 2 (16.6) | |
| 25–30 | 28 (34.1) | 19 (38.7) | 16 (32.6) | 20 (40.8) | 7 (21.8) | 8 (21.6) | 5 (41.6) | |
| ≥30 | 15 (18.3) | 14 (28.5) | 6 (12.2) | 7 (15.5) | 1 (3.1) | 9 (24.3) | 1 (8.3) | |
|
| ||||||||
| Comorbidities | ||||||||
| Yes | 64 (78.1) | 21 (42.8) | 26 (53) | 15 (33.3) | 9 (28.1) | 17 (45.9) | 6 (50) | 0.002 |
| No | 18 (22.0) | 28 (57.1) | 23 (46.9) | 30 (66.6) | 23 (71.8) | 20 (54) | 6 (50) | |
|
| ||||||||
| History of COVID-19 infection | ||||||||
| Yes | 38 (45.2) | 28 (57.1) | 29 (59.1) | 33 (73.3) | 23 (71.8) | 15 (45.5) | 9 (75) | <0.0001 |
| No | 46 (54.8) | 21 (42.8) | 2040.8) | 12 (26.6) | 9 (28.1) | 22 (59.4) | 3 (25) | |
| Menstrual disturbances post-COVID-19 vaccination | 10 (11.9) | 2 (4.08) | 0 | 5 (11.1) | 2 (6.2) | 1 (2.7) | 2 (16.6) | |
∗The post hoc test revealed that only BMI between the COVAXIN + PastoCovac Plus and Sinopharm + PastoCovac Plus groups with a P value of <0.0001 after Bonferroni correction. BMI: body mass index; IQR: interquartile range.